A comprehensive systematic review and meta-analysis of the global data involving 61,532 cancer patients with SARS-CoV-2 infection

Abstract Background SARS-CoV-2 have been shown to be associated with more severe disease and death in cancer patient. A systematic review and meta-analysis was conducted to determine the risk by age, tumour type and treatment of infection with SARS-CoV-2 in cancer patients.Methods Systematic review by searching PubMed, Web of Science, and Scopus for articles published in English up to June 14, 2021 of SARS-CoV-2 infection in &gt;10 patients with malignant disease. Outcomes included factors in patients with malignant disease that may predict a poor outcome from COVID-19 compared to patients without malignant disease, including patient demographics, tumour subtype and cancer treatments. A meta-analysis was performed using random effects model.Results 81 studies were included, totalling 61,532 cancer patients. Haematological malignancies comprised 22.1% (9,672 of 43,676) of cases. Relative risk (RR) of mortality when age and sex matched was 1.69 (95% CI, 1.46-1.95; p&lt;0.001; I2=51%). RR of mortality, versus non-cancer patients, was associated with decreasing age (exp(b)0.96; 95% CI, 0.922–0.994; p=0.028) but not male sex (exp(b)1.89; 95% CI, 0.222–6.366; p=0.83). RR of mortality in those with haematological malignancies versus non-cancer control was 1.81 (95% CI, 1.53-2.95; I2=0.0%). Compared to other cancers, increased risk of death was seen for lung (RR 1.68, 95% CI, 1.45-1.94; p&lt;0.001), genitourinary (RR 1.11; 95% CI, 1.00-1.24; p=0.059) and haematological malignancies (RR 1.42; 95% CI, 1.31-1.54; p&lt;0.001). Breast (RR 0.51; 95% CI, 0.36-0.71; p&lt;0.001) and gynaecological cancers (RR 0.76; 95% CI, 0.62-0.93; p=0.009) had lower risk of death. Receipt of chemotherapy had greatest overall pooled mortality risk of 30% (95% CI, 25-36%; I2=86.97%) and endocrine therapy the lowest at 11% (95% CI, 6-16%; I2=70.7%).Conclusions Cancer patients, particularly younger cancer patients, appear at increased risk of mortality from COVID-19 compared to non-cancer patients. Differences in outcomes were seen based on tumour types and treatment.Highlights <jats:list list-type="simple"><jats:label>-</jats:label>To our knowledge this is the largest review and meta-analysis of COVID-19 in cancer patients with insights into tumour types and therapies.<jats:label>-</jats:label>In unadjusted analysis cancer doubles the risk of COVID-19 related mortality. This decreased when adjusted for age and sex.<jats:label>-</jats:label>Younger cancer patients have the highest risk of mortality when compared to non-cancer COVID-19 patient of a similar age.<jats:label>-</jats:label>Patients with lung, genitourinary and haematological malignancies are at increased risk of mortality, breast and gynaecological cancers are at lower risk.<jats:label>-</jats:label>Patients on chemotherapy have the highest pooled mortality risk with those on endocrine therapy the lowest..

Medienart:	Preprint

Erscheinungsjahr:	2024
Erschienen:	2024

Enthalten in:	bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024

Sprache:	Englisch

Beteiligte Personen:	Khoury, Emma [VerfasserIn] Nevitt, Sarah [VerfasserIn] Madsen, William Rohde [VerfasserIn] Turtle, Lance [VerfasserIn] Davies, Gerry [VerfasserIn] Palmieri, Carlo [VerfasserIn]

Links:	Volltext [lizenzpflichtig] Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.1101/2021.12.18.21267261

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XBI033250235